Posted: November 4, 2021
“DiaPharma is proud to support the NASH Tsunami podcast and its efforts to raise awareness of the NASH epidemic and to make the latest developments easily accessible to everyone, from subject matter experts to laypeople.” – Michael Hambleton, Ph.D., Vice President
DiaPharma offers noninvasive, mechanistic biomarkers for early and biologically plausible indications of changes in disease activity in NASH drug development studies. Analyzing biomarkers like CK18 with the M30®-Apoptosense and M65® ELISAs can provide valuable information to help your drug candidate move forward.
For research use only in the U.S. and Canada. Not for use in diagnostic procedures.